Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7849263 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL11961364 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL11961363 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL8588353 | 1.00 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL10591424 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL10591418 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3TSHR | |
| SCHEMBL5881237 | 0.81 | IDO1 (0.44) | SLC6A4OGA | |
| SCHEMBL11961360 | 0.80 | TMEM97 (0.38) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL1487127 | 0.80 | TMEM97 (0.38) | SLC6A2SLC6A4SLC6A3HTTOGA | |
| SCHEMBL11961357 | 0.80 | TMEM97 (0.38) | SLC6A2SLC6A4SLC6A3HTTOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| EP-1098885-B9 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-05-18 | — | — | EP | disclosed |
| EP-1098885-B1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-6359145-B1 | ADENOSINE DEAMINASE INHIBITOR; ANTIINFLAMMATORY AGENTS; IMMUNOSUPPRESSANT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-19 | — | — | US | disclosed |
| EP-1098885-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-16 | — | — | EP | disclosed |
| WO-2001026605-A2 | IMMUNOSUPPRESSIVE COMPOSITION CONTAINING IL-2 INHIBITOR AND AN ADENOSINE DEAMINASE INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000005217-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS ADENOSINE DEAMINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | SLC6A2 1183/4885SLC6A4 1613/4885SLC6A3 736/4885 |
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | SLC6A2 3694/4885SLC6A4 3811/4885SLC6A3 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.